

Cipla buys skincare product marketing rights worth Rs 90 cr

03 September 2015 | News | By BioSpectrum Bureau

Cipla buys skincare product marketing rights worth Rs 90 cr



The company's skincare products focuses on treating disorders including acne, skin ageing, psoriasis, eczema and dark circles among others.

According to a [report](#) by The Economic Times, Percos for the next five years will continue to manufacture the products, and later transfer the rights to [Cipla](#).

The 18-year-old Percos' has its manufacturing facility in Haridwar, Uttarakhand.

Percos also claims that it has partnered with DRDO (Defence Research and Development Organization) for the development and manufacturing of high altitude sun screen to aid armed forces and civilians who are engaged in work in hostile environments.

Last month, Cipla was the only key bidder for Kremers Urban, the specialty generics drug business of the US \$4 billion Belgian drug maker UCB, and the deal was pegged at US \$1.3 billion.

On September 3, 2015, Cipla at 1400hrs was trading at Rs 659.65, up by 9.60 or 1.48% on the Bombay Stock Exchange (BSE).

Cipla's Q1 FY 2015-16 revenues stood at Rs 3,853 crore compared to Rs 2,720 for the same quarter in the previous fiscal 2014-15.